Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
Globenewswire· 2026-02-09 12:05
Core Insights - Obexelimab demonstrated a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo in the Phase 2 MoonStone trial, indicating significant efficacy in treating Relapsing Multiple Sclerosis (RMS) [1][2] - The 24-week data further confirmed the drug's robust and durable activity, maintaining significant reductions in lesions and improving biomarkers associated with disease activity [3][4] - The safety profile of obexelimab was consistent with previous trials, showing good tolerability without new safety signals [2][3] Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [12] - The company is advancing two late-stage product candidates: obexelimab and orelabrutinib, with obexelimab being the lead candidate targeting B cell activity [12] - Zenas plans to submit a Biologics License Application (BLA) for obexelimab in the second quarter of 2026 and a Marketing Authorization Application (MAA) in the second half of 2026 for Immunoglobulin G4-Related Disease [11][12] Clinical Trial Details - The Phase 2 MoonStone trial enrolled 116 patients and was designed to evaluate the efficacy and safety of obexelimab in RMS, using MRI endpoints to measure treatment outcomes [9] - The trial's primary endpoint was the cumulative number of new gad-enhancing T1 lesions over weeks 8 and 12, with secondary endpoints assessing disease progression through various biomarkers [9] - Following the double-blind phase, patients transitioned to an open-label period to continue treatment and assess long-term outcomes [9] Mechanism of Action - Obexelimab is a bifunctional monoclonal antibody that binds to CD19 and FcγRIIb, inhibiting B cell activity without depleting them, which is crucial for addressing autoimmune diseases [10][12] - The drug's unique mechanism and self-administered subcutaneous injection regimen may effectively target the pathogenic role of B cells in chronic autoimmune conditions [10][12]
Outdoor Holding Company Reports Continued Profitability In Third Quarter Fiscal 2026
Globenewswire· 2026-02-09 12:05
Core Viewpoint - Outdoor Holding Company reported a 7% increase in net revenues to $13.39 million for the third fiscal quarter of 2026, reflecting successful strategic transformations and operational efficiencies [4][6]. Financial Highlights - Net revenues increased by 7% to $13.39 million from $12.52 million [6]. - Gross profit rose to $11.66 million from $10.95 million, maintaining a gross profit margin of approximately 87% [6]. - Operating expenses decreased by $21.76 million year-over-year, highlighting cost discipline and resolution of legal disputes [6]. - Net income before discontinued operations was $1.46 million, compared to a net loss of $(21.18) million in the previous year, marking the second consecutive quarter of net profitability [6]. - Adjusted EBITDA increased to $6.55 million from $4.26 million in the same period last year [6]. - Diluted EPS improved from $(0.18) to $0.01 from continuing operations [6]. Operational Highlights - GunBroker.com showed solid performance with increased engagement from buyers and sellers, benefiting from recent platform investments [5][6]. - Firearm sales increased by 8% despite a nearly 4% decline in adjusted NICS checks, indicating a larger market share [7]. - Total gross merchandise value (GMV) rose by 6.4% to $215.8 million [7]. - Active listings and average order value both grew year-over-year [7]. - The company implemented user experience enhancements on GunBroker.com, including improved seller tools and buyer personalization algorithms [8]. Strategic Initiatives - The company relocated its headquarters from Arizona to Georgia and advanced corporate restructuring initiatives [6]. - Focus on driving sustainable growth through operational efficiency and continuous digital innovation, including expanding premium seller offerings and enhancing pricing tools [10]. - The post-divestiture strategy aims to capture incremental market share and deliver durable profitability over time [10]. - The company ended the quarter with $69.9 million in cash and cash equivalents, an increase from $65.7 million as of September 30, 2025, underscoring its strong cash generation capabilities [9].
Kraig Biocraft Laboratories Poised for Explosive Spider Silk Production Growth
Globenewswire· 2026-02-09 12:05
Core Viewpoint - Kraig Biocraft Laboratories, Inc. has announced a 2026 production plan aiming for a record output of 10 metric tons of recombinant spider silk cocoon per month, establishing a new global benchmark for spider silk manufacturing [1][3]. Group 1: Production Plans - The company will begin large-scale deployment of its proprietary spider silk silkworm eggs within the next 30 days, with production expected to reach full capacity by May [2]. - At full capacity, the output of 10 metric tons per month represents an unprecedented scale in the production of naturally spun recombinant spider silk [3]. Group 2: Technological Advancements - Kraig Labs has engineered proprietary production strains designed for durability, consistency, and high yields of recombinant spider silk, ensuring stability and performance at an industrial scale [4]. - The company has made significant investments in facilities, workforce expansion, and vertically integrated production infrastructure to support this manufacturing platform [5]. Group 3: Market Impact - The CEO of Kraig Labs stated that achieving multi-ton level output will unlock key markets and sales channels, marking a transformative moment for the company and spider silk technology [6].
High-Yield Wreck Your Retirement? Here Is Your Path To Recovery
Seeking Alpha· 2026-02-09 12:05
To celebrate High Yield Investor turning five, we’re offering a 30-day money-back guarantee . Now is the perfect time to join. We are releasing our Top Picks for 2026 , and with the guarantee, you have everything to gain and nothing to lose.Arguably, the biggest mistake retirees often make in investing is having a false sense of security, in particular when investing in double-digit income yields, because it leads them to believe that they are generating more sustainable passiveSamuel Smith has a diverse ba ...
SoFi Technologies (NASDAQ:SOFI) Sees Positive Outlook from Citigroup Upgrade
Financial Modeling Prep· 2026-02-09 12:04
Citigroup upgrades SoFi Technologies (NASDAQ:SOFI) to "Outperform" with a stock price of $20.86.SoFi reports its first $1 billion revenue quarter in Q4 2025 and projects a 30% year-over-year revenue growth and a 52% increase in Adjusted EBITDA for 2026.The company focuses on expanding margins and transitioning towards capital-light, fee-based revenues, with a loan platform performing well and cross-selling efforts reaching 40%.SoFi Technologies (NASDAQ:SOFI) is a financial technology company that offers a r ...
Top crypto stocks to watch this week: HOOD, COIN, MSTR, BMNR
Invezz· 2026-02-09 12:04
Crypto stocks, including digital asset treasury (DAT), exchanges, and miners, have plunged this year as Bitcoin and most altcoins imploded. Bitcoin price plunged to $60,000, while most altcoins fell t... ...
3 Things That Can Ease Stock Market Nerves as Crucial Jobs Report Looms
Barrons· 2026-02-09 12:04
Relax everyone, the stock market will be fine this year according to the Super Bowl Indicator. But even for investors who don't believe the National Football Conference's Seattle Seahawks guaranteed gains this year with their victory, there are reasons to be positive heading into a crucial January jobs report. ...
Cango Inc. Releases 2025 Letter to Shareholders
Prnewswire· 2026-02-09 12:04
Core Insights - The year 2025 was a pivotal chapter for Cango, marking a strategic transformation towards becoming a leading Bitcoin miner and setting the stage for future opportunities in AI compute infrastructure [1][2]. Company Strategy - Cango has executed a disciplined entry into the Bitcoin mining industry, achieving a hashrate efficiency of 50 EH/s and securing 50 MW of energy infrastructure while transitioning to a direct NYSE listing [2][3]. - The company has made treasury adjustments to strengthen its balance sheet and reduce financial leverage, enhancing its capacity for strategic expansion into AI compute infrastructure [3]. Transition to AI Compute - Cango's global mining operations and infrastructure provide a pathway to meet the growing demand for AI compute, addressing the "Power Gap" between compute demand and existing grid capacity [4]. - The transition to AI compute will follow a three-phase roadmap: - Near Term: Standardization and deployment of modular GPU compute nodes for rapid market entry [5]. - Medium Term: Deployment of a proprietary software platform to manage distributed compute capacity [6]. - Long Term: Growth into a mature global AI infrastructure platform, activating underutilized power across the mining ecosystem [7]. Ecosystem Development - Cango aims to create broader ecosystem value by positioning itself as an "Ecosystem Enabler," leveraging underutilized energy infrastructure from the Bitcoin mining industry for AI needs [11]. - The company has established EcoHash Technology LLC to advance its AI compute initiatives, assembling a dedicated team for technical execution [8]. Value Creation - The shift towards a technology-driven infrastructure platform is expected to open new recurring revenue streams, building a resilient business model that complements existing mining operations [13]. - Cango recognizes that the transition from mining to AI compute is a long-term journey, requiring sustained effort and clear execution of its roadmap [14].
5 Things To Know: February 9, 2026
Youtube· 2026-02-09 12:03
Let's talk about five things you need to know ahead of the opening bell. Hong Kong media tycoon Jimmy Lie sentenced to 20 years in prison under a China imposed national security law that has reshaped the city's political landscape. Lie is a China critic and the founder of the now shutdown Apple daily newspaper.President Trump's endorsing NextStar's media's proposed $6.2% billion acquisition of Tegna. In November, the president had come out against that deal and the potential for more TV industry consolidati ...
Vitalist and MicroEJ Partner with BENIO to Launch First VitalOS™ Powered Smartwatch in Asia
Globenewswire· 2026-02-09 12:03
Core Viewpoint - Vitalist Inc. has formed a strategic partnership with MicroEJ and Shenzhen BENIO IoT Technology Co., Ltd to launch a Benio-branded smartwatch powered by VitalOS, targeting the rapidly growing Asian smartwatch market [1][2][3] Group 1: Partnership Details - The partnership includes a multi-year agreement to introduce a smartwatch that will leverage VitalOS technology, marking a significant step in Vitalist's global expansion efforts [2][3] - This collaboration aims to accelerate the adoption of VitalOS in the Asian market, which is characterized by increasing consumer demand for advanced wearable technology [2][3] Group 2: Technology and Market Impact - VitalOS, utilizing MicroEJ's VEE Wear solution, promises up to three times longer battery life and comprehensive third-party app support, while minimizing hardware requirements and manufacturing costs [4][5] - The partnership is expected to enhance the user experience on low-power, affordable hardware, allowing manufacturers like Benio to innovate rapidly while maintaining quality across various market tiers [5] Group 3: Company Profiles - MicroEJ is recognized as a leader in software solutions for intelligent devices, with over 300 million units sold globally, enabling manufacturers to create smart, cloud-connected devices [6] - Benio IoT Technology Co. specializes in consumer electronics and aims to deliver high-quality, feature-rich wearables to a broad consumer base, marking its strategic entry into the smartwatch sector [7]